Kura Oncology (NASDAQ:KURA) drew attention as its oral menin inhibitor gained traction in AML, keeping the biotech in focus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results